Supplementary Figures and Tables from Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Authors: Goodman Aaron M. , Kato Shumei , Bazhenova Lyudmila , Patel Sandip P. , Frampton Garrett M. , Miller Vincent , Stephens Philip J. , Daniels Gregory A. , Kurzrock Razelle 
Published: April 2023

<p>Supplemental Figure 1: Consolidated Standards of Reporting Trials (CONSORT) diagram Supplemental Figure 2: Kaplan Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Supplemental Figure 3: Kaplan Meier curves for patients with melanoma (Panels A and B) and NSCLC (Panels C and D) for treated with anti-PD-1/PD-L1 monotherapy. Supplemental Table 1: Number of patients who received more than one line of treatment with immunotherapy Supplemental Table 2: Patient Demographics by TMB low vs. Intermediate or High (N = 151) Supplemental Table 3: Median TMB for patients treated with immunotherapy agents: responders vs. non-responders Supplemental Table 4: Univariate and multivariate analysis of factors affecting outcome for all patients treated with immunotherapy agents (TMB low vs. intermediate or high) (N = 151) Supplemental Table 5: Univariate and multivariate analysis of factors affecting outcome for patients with all tumor types excluding melanoma and NSCLC treated with immunotherapy agents (TMB low vs. intermediate or high) (N = 63) Supplemental Table 6: Univariate and multivariate analysis of factors affecting outcome for patients with melanoma or NSCLC treated with immunotherapy agents (TMB low or intermediate vs. high) (N = 88) Supplemental Table 7: Univariate and multivariate analysis of factors affecting outcome for patients with melanoma or NSCLC treated with immunotherapy agents (TMB low vs. intermediate or high) (N = 88) Supplemental Table 8: All tumor types including melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low or intermediate vs. high (N = 102) Supplemental Table 9: All tumor types including melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low vs. intermediate or high (N = 102) Supplemental Table 10: CR/PR rate depending on TMB cutoff for patients treated with anti-PD-1/PD-L1 monotherapy (N = 102) Supplemental Table 11: PFS and OS depending on TMB cutoff for patients treated with anti-PD-1/PD-L1 monotherapy (N = 102) Supplemental Table 12: All tumor types excluding melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low or intermediate vs. high (N = 55) Supplemental Table 13: All tumor types excluding melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low vs. intermediate or high (N = 55) Supplemental Table 14: Patients with melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low or intermediate vs. high (N = 47) Supplemental Table 15: Patients with melanoma and NSCLC treated with anti-PD-1/PD-L1 monotherapy - TMB low vs. intermediate or high (N = 47) Supplemental Table 16: Median TMB for patients treated with anti-PD-1/PD-L1 monotherapy: responders vs. non-responders Supplemental Table 17: Total treatments for all tumors Supplemental Table 18: Review of published abstracts and manuscripts utilizing TMB as a predictor of response to treatment with anti-PD-1/PD-L1 agents Supplemental Table 19: Histology, TMB, treatment, are response characteristics for all patients. Supplemental Table 20: Melanoma patients treated with anti-PD-1/PD-L1 monotherapy - TMB low or intermediate vs. high (N = 11) Supplemental Table 21: Melanoma patients treated with anti-PD-1/PD-L1 monotherapy - TMB low vs. intermediate or high (N = 11) Supplemental Table 22: NSCLC patients treated with anti-PD-1/PD-L1 monotherapy - TMB low or intermediate vs. high (N = 36) Supplemental Table 23: NSCLC patients treated with anti-PD-1/PD-L1 monotherapy - TMB low vs. intermediate or high (N = 36)</p>